|
|
Clinical observation on moxifloxacin sequential therapy for healthcare-associated pneumonia |
CHEN Pei-li, GUO Dong-feng, XU Xiao-chun |
(Department of Emergency, Shanghai Gongli Hospital, Shanghai 200135, China) |
|
|
Abstract Objective: To evaluate the clinical efficacy of moxifloxacin sequential therapy on patients with healthcareassociated pneumonia(HCAP). Methods: Sixty-two patients with HCAP hospitalized from January 2010 to January 2013 in the emergency ward of Shanghai Gongli Hospital were randomly divided into two groups, the treatment group(n=31) was administrated 0.4 g moxifloxacin intravenously, once a day, took the same medicine orally when the symptoms were improved, with total treatment course of 8~12 d; and the control group(n=31) was administrated 2.0 g cefotiam intravenously, twice a day, with total treatment course of 10~14 d. The efficacy of two groups was compared. Results: The clinical curative effect rates of moxifloxacin and cefotiam were 93.5% and 71.0%, the bacterial clearance rates were 94.7% and 61.1%, respectively; moxifloxacin was better than cefotiam in clinical curative effect(P<0.05). Conclusion: The anti-infection function of moxifloxacin sequential therapy was effective, meanwhile, with high bacterial clearance rate and clinical value.
|
Received: 14 February 2014
|
|
|
|
\[1\]姚瑜.美国传染病学会/美国胸科学会联合颁布的2007年修订版成人社区获得性肺炎诊疗指南执行概要\[J\].国外医药:抗生素分册,2008,29(2):80-87.\[2\]吴均竹,周作华,吕军眉,等.呼吸道感染病原菌分布及培养结果分析\[J\].实用诊断与治疗杂志,2007,21(5):386-387.\[3\]Moise PA, Birmingham MC, Schentag JJ. Pharmacokinetics and metabolism of moxifloxacin\[J\].Drugs Today(Brac), 2000, 36(4):229-244.\[4\]American Thoracic Society, Infectious Diseases Society of American. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcareassociated pneumonia\[J\].Am J Respir Crit Care Med, 2005,171(4): 388-416.\[5\]蔡柏蔷,李龙芸.协和呼吸病学\[M\].北京:中国协和医科大学出版社, 2005:165-172.\[6\]Wilson R,Macklin-Doherty A. The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis\[J\].Expert Rev Respir Med, 2012, 6(5):481-492.\[7\]Lopes SC, Ribeiro C, Gameiro P. A new approach to counteract bacteria resistance: a comparative study between moxifloxacin and a new moxifloxacin derivative in different model systems of bacterial membrane\[J\].Chem Biol Drug Des, 2012, 81(2):265-274.\[8\]陈玉玲,邵华军,张文辉,等.卫生保健相关性肺炎的临床分析\[J\].中国感染与化疗杂志,2009,9(4):256-259.\[9\]Miravitlles M, Anzueto A.Moxifloxacin:a respiratory fluoroquinolone\[J\].Expert Opin Pharmacother, 2008, 9(10): 1755-1772.\[10\]Wilson R,Anzueto A,Miravitlles M, et al.Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results\[J\].Eur Respir J, 2012, 40(1):17-27.\[11\]McDonald LC.Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment\[J\].Clin Infect Dis, 2006, 42(Suppl 2):S65-S71. |
|
|
|